Colossal Biosciences has raised $1B across 7 funding rounds, plus 4 undated rounds. The latest round valued Colossal Biosciences at $25B rumored.
Colossal has raised more than $555 million in total, including a $150 million Series B in January 2023 that pushed its valuation above $1 billion. By September 2025 it reached a $10.32 billion valuation, and in July 2026 Axios reported the company was in talks to raise new funding at $20 billion to $30 billion.
7 funding rounds, the latest highlighted.
Colossal Biosciences was founded in 2021, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $15M raised, led by Thomas Tull, Tim Draper, Breyer Capital, Winklevoss Capital Management.
A primary round — the company sells new shares to investors it selects. $60M raised, led by Thomas Tull.
A primary round — the company sells new shares to investors it selects. $150M raised.
A primary round — the company sells new shares to investors it selects. $200M raised.
US Innovative Technology Fund, ARCH Venture Partners co-founder Robert Nelsen, filmmaker Peter Jackson. $120M raised.
United Arab Emirates, Crown Prince Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum. $60M raised.
A primary round — the company sells new shares to investors it selects.
No filing has been made.
7 dated rounds, newest first.
Tim DraperLEADTTony RobbinsLEAD
Breyer CapitalLEADWWinklevoss Capital ManagementLEAD
Draper Associates
Animoca BrandsBBold CapitalBBoost VCBBuilders VCGGreen Sands EquityRRichard GarriottPParis HiltonUUntamed PlanetAAnimal Capital
Arch VenturesFFirst Light Capital GroupJJazz Ventures+1 moreLead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Colossal Biosciences is a private company; its shares do not trade on a public exchange.
The last valuation is $25B (rumored, Jul 2026).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
